Long B,Brady W J,Gottlieb M.Emergency medicine updates:atrial fibrillationwith rapid ventricular response[J].Am J Emerg Med,2023,74(17):57-64.
[4]
Hoffer M,Tran Q K,Hodgson R,et al.Utility of magnesiumsulfate in the treatment of rapid atrial fibrillation in the emergencydepartment:a systematic review and meta-analysis[J].Eur J Emerg Med,2022,29(4):253-261.
[5]
Enayati A,Gin J H,Sajeev J K,et al.Efficacy of intravenous magnesium for the managementof non-post operative atrial fibrillation with rapid ventricular response:asystematic review and meta-analysis[J].J Cardiovasc Electrophysiol,2023,34(5):1286-1295.
[6]
Long B,Keim S M,Gottlieb M,et al.What is the best agent for ratecontrol of atrial fibrillation with rapid ventricular response?[J].J Emerg Med,2022,63(3):467-476.
Tchouapi P C,Anderson K E,Hein P N.Intravenous magnesium as an adjunct tostandard of care for treatment of atrial fibrillation with rapid ventricularresponse[J].Acad Emerg Med,2023,30(7):779-781.
[9]
Cicala E,Velicu A C,Gherghina A,et al.Dual Atrioventricular nodal non-reentrant tachycardia misdiagnosed as rapid atrial fibrillation-the role ofadenosine[J].Maedica(Bucur),2022,17(3):735-739.
[10]
Niforatos J D,Ehmann M R,Balhara K S,et al.Management of atrial flutter and atrial fibrillation with rapidventricular response in patients with acute decompensated heart failure:Asystematic review[J].Acad Emerg Med,2023,30(2):124-132.
[11]
Li Q,Fang Y,Peng D W,et al.Sacubitril/valsartan reduces susceptibility to atrial fibrillation by improvingatrial remodeling in spontaneously hypertensive rats[J].Eur J Pharmacol,2023,95(2):175-179.
[12]
Ha S H,Jeong S,Park J Y,et al.Association between rapid ventricular response andstroke outcomes in atrial fibrillation-related cardiac embolic stroke[J].Cerebrovasc Dis,2024,53(1):69-78.
[13]
Nagy S Z,Kasi P,Afonso V X,et al.Cycle length evaluation in persistent atrial fibrillation usingkernel density estimation to identify transient and stable rapid atrialactivity[J].Cardiovasc Eng Technol,2022,13(2):219-233.
[14]
Siddiqui M N,Henley E,Xue B.Refractory atrial fibrillation with rapidventricular response as a heralding sign of propofol infusion syndrome in apatient with COVID-19[J].BMJ Case Rep,2023,16(5):252-263.
[15]
Bishop J J,Akram G.Diltiazem dosing strategies in the management ofatrial fibrillation with rapid ventricular rate[J].Cureus,2021,13(10):188-192.
[16]
Kovacs B,Yakupoglu H Y,Eriksson U,et al.Medical therapy withflecainide and propafenone in atrial fibrillation:Long-term clinical experiencein the tertiary care setting[J].Cardiol J,2023,30(1):82-90.
[17]
Chin C G,Hsieh Y C,Lin W S,et al.An open-label randomizednoninferior study of generic name and brand name of propafenone for rhythmcontrol in patients with paroxysmal atrial fibrillation[J].J Chin Med Assoc,2023,86(5):472-478.
[18]
Okin P M,Hille D A,Wachtell K,et al.On-treatment HDL cholesterol predicts incident atrial fibrillation in hypertensivepatients with left ventricular hypertrophy[J].Blood Press,2020,29(5):319-326.
[19]
Noel J E,Sinclair C F.Radiofrequency ablation for benign thyroid nodules[J].J Clin Endocrinol Metab,2023,109(1):12-17.
Sinen O,Bülbül M.The role of autonomic pathways in peripheral apelin-induced gastrointestinal dysmotility:involvement of the circumventricularorgans[J].Exp Physiol,2021,106(2):475-485.
[24]
Mowaswes M,Biton Y,Belhassen B.Type 1 brugada-electrocardiogram:a rarepresentation in a 57-year-old woman with paroxysmal atrial fibrillation treatedwith a therapeutic dose of propafenone[J].Isr Med Assoc J,2021,23(7):456-458.
[25]
Karelas D,Papanikolaou J,Kossyvakis C,et al.Old stuff stilltrending:use of propafenone as a safety net until catheter ablation in apatient with documented pre-excited atrial fibrillation and wolff-parkinson-white syndrome-a classic case report[J].Eur Heart J,2021,5(12):4-8.
[26]
Huang R,Lin J,Gong K,et al.Comparison of amiodarone and propafenone in blanking period after radiofrequencycatheter ablation in patients with atrial fibrillation:a propensity score-matched study[J].Biomed Res Int,2020,26(18),2020:181-183.
[27]
Taha H S,Youssef G,Omar R M,et al.Efficacy and speed of conversion of recent onset atrial fibrillation using oralpropafenone versus parenteral amiodarone:a randomized controlled comparativestudy[J].Indian Heart J,2022,74(3):212-217.
[28]
Shoemaker M B,Yoneda Z T,Crawford D M,et al.A Mechanistic clinical trial using(r)-versus(s)-propafenone to test ryr2(ryanodine receptor)inhibition for the prevention of atrial fibrillation induction[J].Circ Arrhythm Electrophysiol,2022,15(10):713-718.
[29]
Boriani G,Capucci A,Lenzi T,et al.Propafenone forconversion of recent-onset atrial fibrillation.a controlled comparison betweenoral loading dose and intravenous administration[J].Chest,1995,108(2):355.
Giacobbo A,Soares E V,Bernardes A M,et al.Atenolol removalby nanofiltration: a case-specific mass transfer correlation[J].Water Sci Technol,2020,81(2):210-216.
2024, Vol. 35 
